|
Main
|
|
Note: This record shows only the 20 elements of the WHO Trial Registration Data Set. To view changes that have been made to the source record, or for additional information about this trial, click on the URL below to go to the source record in the primary register. |
|
Register:
|
ClinicalTrials.gov |
|
Last refreshed on:
|
17 October 2012 |
|
Main ID: |
NCT00417066 |
|
Date of registration:
|
22/12/2006 |
|
Primary sponsor: |
|
|
Public title:
|
Flexible GnRH Antagonist vs Flare up GnRH Agonist Protocol in Poor Responders
|
|
Scientific title:
|
The Flexible GnRH Antagonist Protocol Provides Better Results (IVF Outcomes) Than Flare up GnRH Agonist Protocol in Poor Responders |
|
Date of first enrolment:
|
September 2003 |
|
Target sample size:
|
270 |
|
Recruitment status: |
Completed |
|
URL:
|
http://clinicaltrials.gov/show/NCT00417066 |
|
Study type:
|
Interventional |
|
Study design:
|
Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
|
|
|
Countries of recruitment
|
|
Greece
| | | | | | | |
|
Contacts
|
|
Name:
|
Tryfon Lainas, PhD |
|
Address:
|
|
|
Telephone:
|
|
|
Email:
|
|
|
Affiliation:
|
Eugonia |
| | |
|
Key inclusion & exclusion criteria
|
Inclusion Criteria:
- regular menstrual cycle
- 1 or more failed IVF attempts with poor response
- 5 or fewer oocytes retrieved
- FSH>12 IU/l on day 3
Exclusion Criteria:
- PCOS
- Normal responders
Age minimum:
18 Years
Age maximum:
50 Years
Gender:
Female
|
|
Health Condition(s) or Problem(s) studied
|
|
Infertility
|
|
Premature Ovarian Failure
|
|
Intervention(s)
|
|
Drug: Arvekap 0.1mg (Triptorelin, Ipsen, France)
|
|
Drug: Ganirelix 0.25mg (Orgalutran, Organon, The Netherlands)
|
|
Primary Outcome(s)
|
|
Ongoing pregnancy rate per embryo transfer
|
|
Secondary Outcome(s)
|
|
Duration of ovarian stimulation, total rFSH used, estradiol, LH and progesterone concentration on hCG day.
|
|
Number of fertilised oocytes.
|
|
Number of mature oocytes retrieved.
|
|
Secondary ID(s)
|
|
poor responders
|
|
Source(s) of Monetary Support
|
|
Please refer to primary and secondary sponsors
|
|